Alloreactive Memory B Lymphocytes and Anti-HLA Sensitization

Sponsor
University Hospital, Rouen
Study ID
NCT07011238
Status
Recruiting
Apply to this trial

Conditions

  • Kidney Transplant

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Patients meeting HLA immunization criteria — DIAGNOSTIC_TEST
    At enrollment visit, a single sample of a volume of 50 ml of blood will be taken as part of routine care in order to directly and simultaneously explore the clonality (BCR repertoire), the phenotype of membrane markers and the transcriptome of Bmem alloreactive with respect to a restricted panel of HLA alleles chosen according to the HLA antibody reactivity profile of the patients analyzed

Study Details

In transplantation, B lymphocytes are major cellular players in the alloreactive humoral response through the production of antibodies targeting allogeneic HLA molecules expressed by the transplant. In subjects sensitized to HLA antigens, the contribution of pre-existing alloreactive memory B lymphocytes (Bmem) to allograft rejection phenomena after transplantation is now recognized. It has been proposed that the identification of these Bmem during the pre-transplant period could contribute to a better assessment of post-transplant immunological risk, allowing optimization of strategies to prevent humoral rejection. However, knowledge regarding the phenotypic and functional heterogeneity of Bmem as well as their clonal diversity is still extremely limited, not allowing discrimination between pathogenic and non-pathogenic alloreactive humoral responses. Such discrimination requires a better understanding of the modalities of differentiation of alloreactive B lymphocyte responses. To this end, this study aims to characterize the clonal, phenotypic and functional properties of alloreactive Bmem in subjects awaiting renal transplantation and sensitized to HLA antigens.

Key Dates

First listed
Jun 8, 2025
Start date
Apr 17, 2023
Status verified
Feb 2026
Primary completion
Jun 17, 2028
Completion
Jun 17, 2028

Study Design

Enrollment
51 participants (estimated)

Primary Outcome Measure

Level of heterogeneity of alloreactive Bmem targeting HLA alloantigens [ Time Frame: At enrollment visit ]

Central Contacts

Related Studies